Clinical Trial Update: Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating EMLA cream versus nüm Vapocoolant Spray for reducing port access pain and clinic wait times has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• EMLA Cream (lidocaine 2.5% / prilocaine 2.5% topical cream)
• nüm Vapocoolant Spray (ethyl chloride spray)

Snippet

Sponsor: Marianne Hutti | Conditions: Pediatric Cancer | Phase 4 | Status: WITHDRAWN